Lemmon, Barre ANDAs for topical minoxidil clear FDA; Rogaine exclusivity denied.

OTC ROGAINE PRODUCTS DENIED THREE-YEAR WAXMAN/HATCH EXCLUSIVITY by FDA on April 5. As a result of the agency's ruling, Pharmacia & Upjohn's recently-switched minoxidil 2% hair regrowth treatment will enter the OTC market unprotected from competing private-label versions.